IL-6 modulation for COVID-19: the right patients at the right time?
The ongoing pandemic caused by the novel coronavirus SARS-CoV-2 has disrupted the global economy and strained healthcare systems to their limits. After the virus first emerged in late 2019, the first intervention that demonstrated significant reductions in mortality for severe COVID-19 in large-scal...
Main Authors: | Haiming Wei, Binqing Fu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-04-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/4/e002285.full |
Similar Items
-
Why tocilizumab could be an effective treatment for severe COVID-19?
by: Binqing Fu, et al.
Published: (2020-04-01) -
Rebalancing human rights at the time of Covid-19 pandemic
by: Sándor Judit
Published: (2020-01-01) -
HUMAN RIGHTS AND CIVIL LIBERTIES IN THE TIME OF COVID-19
by: Goran Ilik, et al.
Published: (2020-11-01) -
HUMAN RIGHTS AND CIVIL LIBERTIES IN THE TIME OF COVID-19
by: Goran Ilik, et al.
Published: (2020-11-01) -
Nebulized Therapy in the COVID-19 Era: The Right Tool for the Right Patient [Letter]
by: Hess MW
Published: (2020-09-01)